07.01.2021 • News

Ineos Completes BP Aromatics and Acetyls Buy

Ineos completed its $5 billion acquisition of major petrochemicals assets from BP at the end of 2020, gaining 1,700 employees and adding two new subsidiaries, Ineos Aromatics and Ineos Acetyls.

The aromatics and acetyls units comprise businesses that are already leaders in their market segments, boosting Ineos’ profile in areas where it has been underrepresented up to now. The aromatics unit has facilities at six sites with capacity to produce 7.5 million t/y of purified terephthalic acid (PTA) and 2 million t/y of paraxylene (PX). The acetyls company’s portfolio includes acetic acid and a range of derivatives produced at nine sites.

With the deal, financed through borrowing on existing business organized through styrenics arm Ineos Styrolution, production activities at 15 former BP sites in Asia, Europe and the US will transfer to the Swiss-based, UK-managed chemical group.

Unloading the assets will allow BP to concentrate on clean energy, reaching its $15 billion target for agreed divestments a full year ahead of schedule, then-chief financial officer Brian Gilvary, who led the negotiations with Ineos, said at the time.

Gilvary retired from the UK oil group shortly after the deal’s closing, and in December Ineos chairman and majority shareholder Jim Ratcliffe announced the appointment of the ex-oil executive to head a new energy company called Ineos Energy.

To date, Ineos has revealed no information about the energy company apart from saying that it would incorporate all the chemical group’s oil and gas assets and play a major role in its transition to low carbon technologies.

Author: Dede Williams, Freelance Journalist

Ineos completed its $5 billion acquisition of major petrochemicals assets from...
Ineos completed its $5 billion acquisition of major petrochemicals assets from BP at the end of 2020, gaining 1,700 employees and adding two new subsidiaries, Ineos Aromatics and Ineos Acetyls. The new additions, market leaders, will sharpen the chemical group’s profile. (c) Ineos

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

most read